PTC (NASDAQ: PTC) today reported financial results for its fourth fiscal quarter and full fiscal year ended September 30, 2025.

Investing.com - PTC (NASDAQ: PTC) reported third quarter EPS of $3.47, $1.20 better than the analyst estimate of $2.27. Revenue for the quarter came in at $894M versus the consensus estimate of ...

PTC Therapeutics (PTCT) reported $211.01 million in revenue for the quarter ended September 2025, representing a year-over-year increase of 7.2%. EPS of $0.20 for the same period compares to -$1.39 a ...

PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corporate update and financial results for the third quarter ended September 30, 2025.

The biopharmaceutical company posted revenue of $211 million in the period, which also beat Street forecasts. Five analysts surveyed by Zacks expected $175.6 million. PTC Therapeutics expects ...

PTC Inc. (NASDAQ:PTC) shares fell 6.5% after the software company’s first-quarter revenue guidance fell short of investor expectations, overshadowing strong fourth-quar ...

PTC (NASDAQ: PTC) has outperformed the market over the past 10 years by 7.24% on an annualized basis producing an average annual return of 20.37%. Currently, PTC has a market capitalization of $24.39 ...

PTC Industries has received a Purchase Order from Gas Turbine Research Establishment (GTRE), Defence Research and Development ...

Fintel reports that on October 30, 2025, Rosenblatt maintained coverage of PTC (NasdaqGS:PTC) with a Buy recommendation.